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GLIPIZIDE, a sulphonyl-cyclohexylurea derivative, was introduced in 1971.
It was found to be a hypolycaemic of great potency, short action and low toxicity.
This report is concerned with the results following treatment for one year with
the drug in a diabetic clinic in Belfast. The study particularly examined the effect
of the drug on patients of differing degrees of obesity and also examined the
effect of the drug in patients who had been on previous sulphonylurea therapy.
PATIENTS AND METHODS
Diabetics admitted to this study were patients in whom the disease was
discovered after the age of 40 and who were not ketotic. All were treated as out-
patients and continued their usual life. Details of the population studied are
shown in Table I. Patients not on previous therapy were only admitted to the
TABLE I
59 patients Age 59.9+10.4 (Mean±SD) Percent ideal weight 113.7±21.2
Previous therapy 16
No previous therapy 32
Per cent Age No.
Ideal Wt.
Gross Obesity >130 59.6± 7.5 13
Obese 111-130 60.3±10.4 17
Normal 91-110 61.9±11.5 18
Underweight >91 56.0± 7.6 4
study if 3 months of dietary treatment failed to produce a satisfactory reduction
in blood glucose. Glipizide was given as a single dose of 5-10 mgs and if increased
to 15-20 mgs daily was then given in divided doses. Patients were given dietary
advice appropriate for their degree of obesity. Measurements of blood glucose
were made on fasting and two hour postprandial blood samples. Weights were
converted to percentage ideal weight from the normals of the Metropolitan Life
Insurance Tables. All patients were asked about possible side effects of the drug.
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The blood glucose values in the various groups before and after treatment
are shown in Table II. At one year there was a significant fall in both fasting
TABLE II
FASTING POST PRANDIAL
Initial 1 year Initial 1 year
Total 13.4±4 8.8±3.3*** 17.4+5.4 12.0±4 ***
Previous therapy 12.6+4.3 9.1 3.77** 16.2±4.7 12.2±3.6**
No previous therapy 13.6+3.8 8.7+3 *** 18.1+5.6 11.6+4.3***
Gross obesity 14.4±3.8 10.lI3.6** 16.7+7.3 12.3+4.7**
Obese 13.0+3.8 9.2±3.3** 15.9+4.9 12.4±4.3**
Normal 12.5+±3.7 7.4±3.4*** 18.9+7.3 11.1 ±4.8***
Underweight 13.8+±4.5 10.6±8.3* 17.8-+5.7 14.3 1.4*
Fasting and postprandial blood glucose levels before and 1 year after treat-
ment with glipizide
*p<.O5 **p<.Ol ***p<.OOl
and postprandial glucose in all groups. The initial blood glucose values in all
groups were similar and the responses were not significantly different in each
group although numbers were small. Of particular note is that fact that treatment
with glipizide produced a significant fall in blood glucose in those whose previous
treatment with Sulphonylureas had not been satisfactory. No significant change
in weight was noted and there was no individual correlation between the improve-
ment in blood glucose and weight change. The average dose of glipizide used was
11 mgs and no significant side effects were noted.
DISCUSSION
The controversy regarding the relationship of control of blood glucose to
the development of microvascular complications still continues. Nevertheless,
the evidence has been interpreted as suggesting that complications are reduced
if blood glucose control can be improved (Cahill et al 1976). Microvascular
complications are problems both in juvenile and maturity onset patients. While
dietary treatment may achieve normal glucose tolerance in many maturity onset
patients a significant number lack the discipline and motivation required for the
success of this regime. Our study demonstrates that glipizide, a second genera-
tion sulphonylurea significantly lowers blood glucose levels. As many of these
patients had failed to improve on dietary treatment alone it is unlikely that the
decrease in blood glucose could be explained by dietary compliance over the
year of glipizide treatment. That improved dietary compliance is improbable
is also suggested by the fact that no group lost weight over the period of study.
Our patients had no significant side effects. The study thus confirms the evidence
of previous trials on the efficacy of glipizide. A preliminary multicentre trial on
661064 diabetic patients reported by Emanueli et al 1972 showed it to give favour-
able control in 80 per cent of maturity onset diabetics when used in doses of
2.5 mgs. It was considered to have equivalent activity to glibenclamide. A further
multicentre trial co-ordinated by Lahon and Mann (1973) was performed on 177
maturity onset diabetics to compare glipizide with glibenclamide, chlorpropamide
and phenformin. Little difference between the efficacy of the various compounds
was seen. Side effects were minimal with glipizide and the doses used with safety
were increased to 30 mg/day.
Pharmacological studies summarized by Artini et al (1973), Tomassia (1975),
Domingo-Gutierrez and Fernandez-Cruz (1975) show that glipizide, unlike
glibenclamide is rapidly absorbed and produces an early insulin release at 30-60
min returning to basal levels by 90 min. It would be reasonable to conclude that
clinical experience with the two drugs might be different; whereas glibenclamide
could be given in one dose daily, glipizide might need divided dosage. Under
clinical conditions the experience of Person (1973) in 19 patients, was that in
patients requiring 10 mg or less of glipizide per day the drug could be given in
one morning dose, whereas a daily dose of over 10mg was given in two doses
morning and evening. Our practical experience was similar. Long-term results
over a four year period on 72 patients formed the basis of the conclusion of
Perodi and Caputo (1975) that the hypoglycaemic action of glipizide did not
decrease with time and the drug was non-toxic. Another long-term study by
Woodruffe (1975) included 22 out of 28 patients who had been satisfactorily
treated for over 12 months. Lebouc and Derot (1975) evaluating 50 maturity
onset diabetics over several months, 9 completing one year's treatment con-
firmed its effectiveness on reducing blood sugars. In this study weight gain on
glipizide unlike most sulphonylureas was minimal which is similar to our
experience. Alexander et al (1975) gave preliminary findings in 23 diabetics who
had been placed on a year trial which was not completed at that date. They
thought it effective but not giving better results that other sulphoonylureas.
However in our study an important feature was the improvement in blood
glucose in patients previously treated with sulphonylureas. The incidence of
of failure of sulphonylurea therapy has been reported as up to 5 per cent per
year (Williams and Porte 1974).Our investigation would suggest that glipizide
may be of value in patients when treatment has failed with other forms of
sulphonylurea therapy.
In conclusion our study which is comparable to other long term trials con-
firms that glinizide is a safe effective oral agent and without significant effects
on the body weight.
SUMMARY
Fifty-two patients with maturity onset diabetes were treated with glipizide
(Minodiab) under the conditions of routine practice of a dibetic clinic.
Blood sugar control was assessed after completion of one year's treatment.
Percentage ideal weights were compared at the beginning and the end of the
period. Patients were subdivided into grossly obese, overweight, normal and
67underweight groups. Improvement in the mean fasting and post-prandial blood
sugars was observed in all groups. Significant improvement over previous therapy
was observed. In conclusion glipizide in doses from 5-20 mg appeared an effective
and non-toxic sulphonylurea under the conditions of clinical practice. Our findings
would confirm long term trials elsewhere.
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